Stockscreener 앱 받기
0.512
2.40%
0.012
Evogene Ltd 주식(EVGN)의 최신 뉴스
Kfir Silberman Pushes for Board Changes at Evogene with 12.61% Stake - TradingView
Evogene (EVGN) investors with 12.61% and 4.13% stakes seek major board changes - Stock Titan
Evogene and Tel Aviv University launch drug discovery initiative - Pharmaceutical Business review -
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery - Global Agriculture
Evogene and Tel Aviv University team up to speed small-molecule drug discovery - Stock Titan
Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery - marketscreener.com
Evogene Partners with Tel Aviv University on AI Drug... - AllSci
Evogene and Tel Aviv University to accelerate AI-driven small-molecule drug discovery - BioSpectrum Asia
Evogene partners with Tel Aviv University center on drug discovery - Investing.com
Evogene partners with Tel Aviv University center on drug discovery By Investing.com - Investing.com Canada
How Evogene is changing the future for the pharma and agriculture markets - The Jerusalem Post
Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits
Evogene | 6-K: Report of foreign private issuer (related to financial reporting) - Moomoo
Price to book forward of Evogene Ltd. – NASDAQ:EVGN - TradingView
Enterprise value to revenue forward of Evogene Ltd. – NASDAQ:EVGN - TradingView
Evogene Ltd Actuals & Estimates (NASDAQ:EVGN) - TradingView
EVGN Forecast — Price Target — Prediction for 2027 - TradingView
Evogene completes milestone in Google Cloud collaboration By Investing.com - Investing.com South Africa
Evogene completes milestone in Google Cloud collaboration - Investing.com
Evogene Announces Major Milestone in Its Coll - Moomoo
Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization - Nasdaq
Evogene integrates AI agentic systems with Goog... - Pluang
Evogene Ltd (EVGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evogene StockWeekly review and sector context after recent Q1 update - Ad-hoc-news.de
Evogene Ltd (EVGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Evogene Ltd (EVGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Evogene Ltd (EVGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Evogene Ltd (EVGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Evogene Ltd (EVGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evogene Ltd (EVGN) Institutional Confidence - TradingKey
Evogene Ltd (EVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Evogene Ltd (EVGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
EVGN Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin Amid Weak Operating PerformanceEarnings Cycle Report - dars.gov.et
Evogene Showcases AI-Driven ChemPass Platform and Expanded Google Cloud Collaboration in New Investor Deck - TipRanks
Evogene (EVGN) showcases ChemPass AI drug and ag-chem discovery strategy - Stock Titan
EVGN Q1 2026 Earnings: Deep EPS Miss Raises Investor Concerns Amid Pre-Revenue StageTrough Earnings Signal - newsline.com
Biomica CEO Set to Attend JP Morgan Healthcare Week in San Franc - GuruFocus
Evogene Shares Slip 2.6% as Biotech Stock Tests Key Support Level (EVGN)Flat Correction - newsline.com
Evogene Sets Up $2.9 Million At-the-Market Share Offering With A.G.P. - The Globe and Mail
Evogene enters sales agreement for at-the-market offering of up to $2.93 million - Investing.com Australia
Evogene enters sales agreement for at-the-market offering of up to $2.93 million By Investing.com - Investing.com India
Evogene Ltd. (NASDAQ: EVGN) launches $2.93M ATM program with A.G.P. - Stock Titan
Evogene (EVGN) launches $2.93M at-the-market share offering with A.G.P. - Stock Titan
EVGN Q1 2026 Earnings: Significant EPS Miss Amid Ongoing Operational ChallengesBasic EPS Analysis - newsline.com
Evogene Q1 revenue falls to $0.3 million amid strategic shift - scanx.trade
Full Transcript: Evogene Q1 2026 Earnings CallEvogene (NASDAQ:EVGN) - Benzinga
Evogene to Present Its Pharma Division Achievements at the BIO International Convention - PR Newswire
Earnings Call Summary | Evogene(EVGN.US) Q1 2026 Earnings Conference - 富途牛牛
EVGN Stock Price, Quote & Chart | EVOGENE LTD (NASDAQ:EVGN) - ChartMill
Evogene Reports Positive Phase 1 Data for BMC128 in Cancer - t.co
Evogene completes phase 1 trial of BMC128 cancer treatment By Investing.com - Investing.com South Africa
Evogene: Q1 Earnings Snapshot - AOL.com
Evogene (EVGN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Evogene says Phase 1 clinical study of BMC128 met primary endpoint - TipRanks
Evogene completes phase 1 trial of BMC128 cancer treatment - Investing.com
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica - PR Newswire
2.64%
자본화:
|
볼륨(24시간):